Headache Disorders Global Market Report 2024

The headache disorders market size has grown strongly in recent years. It will grow from $4.37 billion in 2023 to $4.7 billion in 2024 at a compound annual growth rate (CAGR) of 7.4%. The growth observed in the historic period can be attributed to various factors, including limited treatment options for headache disorders, increased awareness about these conditions, a rising incidence of headaches, the development of healthcare infrastructure, and shifts in lifestyle leading to elevated stress levels.

The headache disorders market size is expected to see strong growth in the next few years. It will grow to $6.42 billion in 2028 at a compound annual growth rate (CAGR) of 8.1%. The anticipated growth in the forecast period can be attributed to various factors, including the adoption of digital health solutions, personalized medicine approaches, a rise in research and development investments, the global aging population, and an expanded focus on neuroinflammation research. Key trends expected in the forecast period encompass technological advancements in treatment, the implementation of personalized medicine strategies, an increased emphasis on preventive therapies, a growing pipeline of novel therapies, and a rise in the adoption of non-pharmacological approaches.

The headache disorders market is anticipated to experience growth due to the increasing prevalence of migraine. Migraine, characterized by recurring episodes of moderate to severe throbbing and pulsating pain on one side of the head, can lead to neurological disorders causing debilitating throbbing pain, fatigue, and nausea. According to Migraine.com, around 39 million people in the United States and 1 billion people worldwide suffered from migraines in 2021, underscoring the significant demand for the headache disorders market.

The growth of the headache disorders market is expected to be propelled by an increased focus on personalized medicine. Personalized medicine, also known as precision medicine, involves tailoring medical decisions and interventions to individual characteristics. In the context of headache disorders, personalized medicine incorporates individualized approaches based on genetic, molecular, and lifestyle factors to optimize therapeutic outcomes for each patient. In 2021, the FDA's CDER approved 50 new molecular entities, with 17 of them (35%) classified as personalized medicines by The Personalized Medicine Coalition. This focus on personalized medicine is driving advancements in the headache disorder market.

A key trend in the headache disorder market is product innovation, with major companies concentrating on developing innovative products to enhance their market position. For instance, in September 2021, AbbVie, a pharmaceutical company, launched QULIPTATM, a prescription medicine for the preventative treatment of episodic migraine in adults. QULIPTATM is uniquely formulated with an oral calcitonin gene-related peptide (CGRP) receptor antagonist in three different dose sizes, approved by the U.S. Food and Drug Administration (FDA).

Major companies in the headache disorder market are seeking approval for advanced delivery using precision olfactory delivery (POD) technology for the acute treatment of migraine. Precision Olfactory Delivery (POD) Technology is a proprietary drug delivery system designed to administer therapeutic agents through the upper nasal space, offering a non-oral and potentially more effective route of drug delivery. In September 2021, Impel NeuroPharma Inc received FDA approval for TRUDHESA, a nasal spray for the acute treatment of migraine in adults, utilizing POD technology to provide rapid, sustained, and consistent relief without injection.

In May 2022, Man and Science SA, a medical device company based in Belgium, acquired Palion Medical AS for an undisclosed amount. This acquisition aligns with Man and Science's headache treatment offerings, enhancing its ability to provide various therapy solutions to improve patient care. Palion Medical AS, a clinical-stage medical device company based in Germany, focuses on developing a precision injection solution for individuals suffering from debilitating chronic migraine and cluster headaches.

Major companies operating in the headache disorders market report are Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Dr. Reddy's Laboratories Ltd, Novartis AG, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Sun Pharmaceutical Industries Ltd, Emcure Pharmaceuticals Limited, Endo International plc, WorldMeds LLC, AstraZeneca plc, Bausch & Lomb Incorporated, Nichi-Iko Pharmaceutical Co, Upsher-Smith Laboratories LLC, Bristol-Myers Squibb Company, Bayer AG, Boehringer Ingelheim International GmbH., Gilead Sciences Inc., Amgen Inc., Mylan N.V., Pfizer Inc., GlaxoSmithKline plc, Allergan plc, Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Eisai Co. Ltd., Impax Laboratories LLC, Lannett Company Inc., Lupin Pharmaceuticals Inc.

North America was the largest region in the headache disorders market in 2023. The regions covered in the headache disorders market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the headache disorders market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of headache disorders include migraine, tension-type headaches, cluster headaches, medication-overuse headaches, and others. Migraine headaches are distinguished by intense throbbing pain or pulsating sensations, usually localized on one side of the head. Various treatments for headache disorders include medications, heat therapy, dietary modifications, acupuncture, and oxygen therapy. Diagnosis involves procedures such as complete blood count, skull x-rays, sinus x-rays, CT scans, and magnetic resonance imaging (MRI). Treatment methods encompass oral administration, parenteral routes, and other modalities, with applications in hospitals, specialty clinics, homecare, and other healthcare settings.

The headache disorders market research report is one of a series of new reports that provides headache disorders market statistics, including headache disorders industry global market size, regional shares, competitors with headache disorders market share, detailed headache disorders market segments, market trends, and opportunities, and any further data you may need to thrive in the headache disorders industry. This headache disorders market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.